ストックスクリーナーアプリを入手
1.35
3.57%
-0.05
プレマーケット:
1.39
0.04
+2.96%
前日終値:
$1.40
開ける：
$1.4
24時間の取引高:
1.52M
Relative Volume:
0.96
時価総額：
$205.96M
収益：
$137.74M
当期純損益:
$-27.97M
株価収益率:
-8.4375
EPS:
-0.16
ネットキャッシュフロー:
$-9.61M
1週間 パフォーマンス:
-26.63%
1か月 パフォーマンス:
-36.32%
6か月 パフォーマンス:
-24.16%
1年 パフォーマンス:
-27.42%
1日の値動き範囲:
$1.3146
$1.41
1週間の範囲:
$1.19
$1.47
52週間の値動き範囲:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
名前
Heron Therapeutics Inc
セクター
電話
(858) 251-4400
住所
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
HRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.35 | 214.61M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2024-04-23 | 開始されました | CapitalOne | Overweight |
| 2024-03-13 | 繰り返されました | Needham | Buy |
| 2020-05-27 | 開始されました | Guggenheim | Buy |
| 2020-02-20 | 繰り返されました | Needham | Buy |
| 2019-01-16 | 繰り返されました | Needham | Buy |
| 2018-04-05 | 開始されました | Evercore ISI | Outperform |
| 2018-03-19 | 繰り返されました | Mizuho | Buy |
| 2018-03-01 | 繰り返されました | Needham | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Outperform |
| 2017-09-27 | 開始されました | Northland Capital | Outperform |
| 2017-02-27 | 開始されました | Needham | Buy |
| 2016-10-26 | 開始されました | Aegis Capital | Buy |
| 2016-09-06 | 再開されました | Lake Street | Buy |
| 2016-05-03 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-12-10 | 開始されました | Lake Street | Buy |
| 2015-09-23 | 繰り返されました | Leerink Partners | Outperform |
| 2015-09-02 | 開始されました | BofA/Merrill | Buy |
| 2015-08-03 | 繰り返されました | Brean Capital | Buy |
| 2015-06-30 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2015-06-19 | 繰り返されました | Leerink Partners | Outperform |
| 2014-08-07 | 開始されました | Noble Financial | Buy |
すべてを表示
Heron Therapeutics Inc (HRTX) 最新ニュース
XTX Topco Ltd Sells 213,080 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Insider Buying: Heron Therapeutics, Inc. (NASDAQ:HRTX) Major Shareholder Acquires 2,387,225 Shares of Stock - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results - MarketBeat
Insider Buying: Heron Therapeutics, Inc. (NASDAQ:HRTX) Director Purchases 1,766,546 Shares of Stock - MarketBeat
Heron Therapeutics Signs Agreement with Patheon - MSN
Heron Therapeutics’ Earnings Call Highlights Growth and Strategy - TipRanks
Informed Momentum Co LLC Invests $768,000 in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Needham & Company LLC Cuts Heron Therapeutics (NASDAQ:HRTX) Price Target to $3.00 - MarketBeat
Heron Therapeutics Strengthens Financial Position with Refinancing - MSN
Heron Therapeutics (NASDAQ:HRTX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Warner Bros Discovery Director Buys $3.55M Worth of WBD Shares, Heron Therapeutics Director Purchases $2.65M Worth of HRTX Shares - AInvest
Heron Therapeutics Soars 13.74% on Insider Buying, Strategic Moves - AInvest
Rubric Capital and Director Morgan Make Significant Investments in Heron Therapeutics - AInvest
Heron Therapeutics Strengthens Financial Position with Refinancing and Board Changes - AInvest
Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m - Investing.com
Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m By Investing.com - Investing.com UK
Heron Therapeutics enters board agreement and completes refinancing transactions By Investing.com - Investing.com Nigeria
Heron Therapeutics: Insider Confidence and Strategic Entry Points in a Volatile Market - AInvest
Heron Therapeutics enters board agreement and completes refinancing transactions - Investing.com
Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher - Investing.com
Heron Therapeutics Convertible Notes - Leerink Partners
Heron Therapeutics Senior Credit Facility - Leerink Partners
Heron Therapeutics Reports Strong Q2 Revenue Growth Amid Inventory Challenges and Transition to Permanent J Code for Zenerlef - AInvest
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Heron Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Heron Therapeutics announces capital restructuring to support growth - MSN
Heron Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies Financial Group Inc. Buys Shares of 322,600 Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Heron Therapeutics Announces Strategic Financial Initiatives - The Globe and Mail
Heron Therapeutics 2025 Q2 Earnings Record Net Income and Revenue Growth - AInvest
Heron Therapeutics' Q2 Earnings Miss: A Misunderstood Catalyst for Long-Term Growth? - AInvest
Heron Therapeutics' Q2 2025 Earnings: Strategic Momentum Outpaces Short-Term Setbacks - AInvest
Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
TD Asset Management Inc Acquires New Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Reports Strong Q2 2025 Results - TipRanks
Heron Therapeutics: Needham Adjusts Price Target to $3.00 - AInvest
Heron Therapeutics Raises EBITDA Guidance to $9M-$13M for 2025 Amid Restructuring and ZYNRELEF J-code Milestone - AInvest
Heron Therapeutics HRTX Q2 2025 Earnings Preview Upside Potential Amid Product Expansion - AInvest
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 - The Malaysian Reserve
Heron Therapeutics' Q2 2025 Performance and Strategic Realignments: A Blueprint for Long-Term Growth - AInvest
Heron Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:HRTX) - Seeking Alpha
Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone - MSN
Heron Therapeutics Reschedules Q2 2025 Earnings Release and Conference Call to August 8, 2025 - AInvest
Heron Therapeutics Plummets 28%: What's Fueling the Sudden Sell-Off? - AInvest
Transcript : Heron Therapeutics, Inc., Q2 2025 Earnings Call, Aug 08, 2025 - MarketScreener
Heron Therapeutics Trims Debt And Lifts Yearly Outlook - Finimize
Earnings call transcript: Heron Therapeutics faces Q2 2025 earnings miss, stock drops - Investing.com Canada
Heron Therapeutics Tightens Its Belt And Lifts Its Outlook - Finimize
Heron Therapeutics Q2 2025 slides: Revenue grows, guidance raised despite stock plunge - Investing.com Canada
Heron Therapeutics Inc (HRTX) 財務データ
収益
当期純利益
現金流量
EPS
Heron Therapeutics Inc (HRTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
0.11%
1.56%
大文字化:
|
ボリューム (24 時間):